Enhanced Delivery of Erythropoietin Across the Blood-Brain Barrier for Neuroprotection Against Ischemic Neuronal Injury

Translational Stroke Research

Volumn 1, Issue 2, 2010, Pages 113-121

  Zhang, Feng ^a,c   Xing, Juan ^a,c   Liou, Anthony Kian Fong ^c   Wang, Suping ^a,c   Gan, Yu ^c   Luo, Yumin ^b   Ji, Xuming ^b   Stetler, R Anne ^a,c   Chen, Jun ^a,c   Cao, Guodong ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Drug delivery system; Erythropoietin; HIV TAT protein; Ischemia brain; Neuroprotection

Indexed keywords

ERYTHROPOIETIN; HYBRID PROTEIN; N METHYL DEXTRO ASPARTIC ACID; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; EMBRYO; HUMAN; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 77955851806     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-010-0019-3     Document Type: Article

References (28)

1. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97(19): 10526-10531.
2. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M et al (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95(8): 4635-4640.
3. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8(8): 495-505.
4. Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6(6): 484-494.
5. Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M (2001) Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab 21(7): 857-864.
6. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8): 459-460.
7. Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL (1997) Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 78(6): 1505-1509.
8. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK (2003) Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98(7): 1514-1520.
9. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR et al (2002) In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 22(13): 5423-5431.
10. Kilic U, Kilic E, Dietz GP, Bahr M (2003) Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34(5): 1304-1310.
11. Yin W, Cao G, Johnnides MJ, Signore AP, Luo Y, Hickey RW et al (2006) TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis 21(2): 358-371.
12. Chen J, Nagayama T, Jin K, Stetler RA, Zhu RL, Graham SH et al (1998) Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. J Neurosci 18(13): 4914-4928.
13. Frankmann SP (1986) A technique for repeated sampling of CSF from the anesthetized rat. Physiol Behav 37(3): 489-493.
14. Cao G, Pei W, Lan J, Stetler RA, Luo Y, Nagayama T et al (2001) Caspase-activated DNase/DNA fragmentation factor 40 mediates apoptotic DNA fragmentation in transient cerebral ischemia and in neuronal cultures. J Neurosci 21(13): 4678-4690.
15. Cao G, Clark RS, Pei W, Yin W, Zhang F, Sun FY et al (2003) Translocation of apoptosis-inducing factor in vulnerable neurons after transient cerebral ischemia and in neuronal cultures after oxygen-glucose deprivation. J Cereb Blood Flow Metab 23(10): 1137-1150.
16. Chong ZZ, Maiese K (2007) Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 150(7): 839-850.
17. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305(5681): 239-242.
18. Ranchon Cole I, Bonhomme B, Doly M (2007) Pre-treatment of adult rats with high doses of erythropoietin induces caspase-9 but prevents light-induced retinal injury. Exp Eye Res 85(6): 782-789.
19. Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE (2007) Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res 61(6): 671-675.
20. Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA (2004) Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate 85(2): 138-144.
21. Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A et al (2002) Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA 99(8): 5627-5631.
22. Doeppner TR, Nagel F, Dietz GP, Weise J, Tonges L, Schwarting S et al (2009) TAT-Hsp70-mediated neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 29(6): 1187-1196.
23. Zhou M, Xu W, Liao G, Bi X, Baudry M (2009) Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1alpha truncation. Exp Neurol 218(1): 75-82.
24. Xenocostas A, Cheung WK, Farrell F, Zakszewski C, Kelley M, Lutynski A et al (2005) The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 61(3): 189-195.
25. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M et al (2003) Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 100(11): 6741-6746.
26. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M et al (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 105(31): 10925-10930.
27. US Food and Drug Administration (2008) Early communication about an ongoing safety review epoetin alpha. US Food and Drug Administration.
28. Lieutaud T, Andrews PJ, Rhodes JK, Williamson R (2008) Characterization of the pharmacokinetics of human recombinant erythropoietin in blood and brain when administered immediately after lateral fluid percussion brain injury and its pharmacodynamic effects on IL-1beta and MIP-2 in rats. J Neurotrauma 25(10): 1179-1185.